Investors
Investing in the interpretation layer of medicine.
Sequencing is commoditising; interpretation is the durable, defensible layer. Soma Nova is raising a Series A to build it — and take it to market in India and the UK.
Sequencing is commoditising; interpretation is the durable, defensible layer. Soma Nova is raising a Series A to build it — and take it to market in India and the UK.
Whoever owns the trusted, explainable interpretation of the genome owns the most durable position in genomic medicine. That’s the layer we’re building.
Deepen the interpretation engine, Digital Twin and the three product layers.
Anchor-site pilots generating evidence in rare disease and oncology.
Certifications and the path toward regulated clinical use.
Commercial motion across India and the UK.
Founding hires across clinical genomics, AI and engineering.
FHIR/GA4GH integration with health-system partners.
Partner deployments in India and the UK — defined case volume, named reviewers, structured feedback.
Concordance and turnaround data across rare disease and oncology.
Expand solutions and health-system integrations; open the US horizon.
Detailed materials, financials and traction are available to qualified investors under NDA.
For professional / qualified investors only. Not an offer of securities.